Viking Therapeutics VKTX
- Market cap
- $3.4B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/a
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $0
- Net margin
- n/a
- Free cash flow yield
- n/m
- not a meaningful number
Viking Therapeutics' trailing earnings are negative, so it has no PE. Revenue was $0 over the last twelve months.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| R&D | $20.5M+27% | $24.1M+119% | $23.8M+71% | $22.8M+24% | $31M+51% | $41.4M+72% | $60.2M+153% | $90M+295% | $153.5M+395% | $150.2M+263% | $115.8M+92% | $166.8M+85% |
| SG&A | $8.8M+114% | $10M+5% | $10.3M+5% | $13.8M+55% | $15.3M+74% | $14.1M+41% | $14.4M+40% | $8.6M−38% | $11.3M−26% | $14M−1% | $16.8M+17% | $20.3M+136% |
| −$29.3M+44% | −$34.1M+66% | −$34.1M+43% | −$36.6M+34% | −$46.2M+58% | −$55.5M+63% | −$74.6M+119% | −$98.6M+170% | −$164.7M+256% | −$164.1M+196% | −$132.6M+78% | −$187.1M+90% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $88K |
| Net income | −$24.6M+26% | −$27.4M+40% | −$22.3M+16% | −$24.9M+11% | −$35.4M+44% | −$45.6M+67% | −$65.6M+195% | −$90.8M+264% | −$157.7M+345% | −$158.3M+247% | −$128M+95% | −$183.2M+102% |
| −$0.25−4% | −$0.26+4% | −$0.20+5% | −$0.22−4% | −$0.32+28% | −$0.41+58% | −$0.58+190% | −$0.81+268% | −$1.38+331% | −$1.37+234% | −$1.10+90% | −$1.55+91% | |
| 99.9M+30% | 103.5M+32% | 110.4M+12% | 110.9M+11% | 111.3M+12% | 112.1M+8% | 112.1M+2% | 112.3M+1% | 114M+2% | 115.6M+3% | 116.3M+4% | 118M+5% |
EPS, diluted: 12 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY14: share-days: the 12-month average less the 9-month, weighted by days. 11 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Viking Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VKTXViking Therapeutics | $3.4B | n/m | n/a | n/a | n/m | n/a | |
| OGNOrganon | $3.6B | 18.2× | 6.0× | 0.6× | −3% | 3.5% | |
| LQDALiquidia | $3.7B | 30.1× | 49.4× | 8.3× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 117× | 8.5× | +76% | 6.1% | |
| NRIXNurix Therapeutics | $2.8B | 11.1× | 11.0× | 4.0× | n/m | 42.0% | |
| INDVIndivior Pharmaceuticals | $4.3B | 10.2× | 19.9× | 3.1× | +16% | 32.8% | |
| PBHPrestige Consumer Healthcare | $2.4B | 13.9× | 15.3× | 2.1× | −1% | 15.6% | |
| HRMYHarmony Biosciences | $2.2B | 12.3× | 13.8× | 2.3× | +24% | 18.9% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.7× | 37.6× | 21.1× | +55% | 67.9% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.7× | 51.4× | 2.1× | +9% | 5.0% | |
| KNSAKiniksa Pharmaceuticals International | $7.1B | 93.6× | 87.6× | 8.4× | +59% | 9.6% | |
| Peer median | $3.8B | 24.1× | 28.8× | 3.6× | +20% | 17.2% |
More on Viking Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .